News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Deals
Genzyme Corporation Chief Could Reap $221.2M in Sanofi-Aventis (France) Deal
March 8, 2011
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Xconomy -- Genzyme chief executive Henri Termeer is due to take in $158.4 million from French drug giant Sanofi-Aventis’s buyout of his Cambridge, MA-based biotech firm, Bloomberg reported.
Twitter
LinkedIn
Facebook
Email
Print
Mergers & acquisitions
Sanofi
MORE ON THIS TOPIC
Immunology and inflammation
Apogee investors riled by $1.3B royalty deal, as eczema drug matches Lilly’s Ebglyss
May 27, 2026
·
3 min read
·
Annalee Armstrong
Vaccines
Lilly just bought renowned regulator Peter Marks a pipeline to play with
May 27, 2026
·
2 min read
·
Annalee Armstrong
Podcast
Lilly wheels and deals, Moderna gets boost on hantavirus scare, ASCO excitement builds
May 27, 2026
·
2 min read
·
Jef Akst
Insights
Germany can produce biotech winners. Europe must back them better.
May 27, 2026
·
4 min read
·
Jennifer C. Smith-Parker
